Combined inhalers vs LABA: Exacerbations (number of people experiencing ≥ 1 exacerbations)
Combined inhalers probably leads to lower number of people experiencing one or more exacerbations compared with LABAs (moderate certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Combined inhalers vs LABAs Number of people experiencing one or more exacerbations · COPD Combined inhalers probably leads to lower number of people experiencing one or more exacerbations compared with LABAs (moderate certainty). Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for… (2012) · Cochrane Headline outcomes only | OR 0.83 [0.7, 0.98] | 6 studies · 3357 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Combined corticosteroid and long‐acting beta₂‐agonist in one inhaler versus long‐acting beta₂‐agonists for chronic obstructive pulmonary… 2012 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.